Techkrates logo Techkrates
Contact
DE EN

← Back to Insights

FDA CSA for MedTech Software: Risk-Based Assurance and Evidence

FDA Computer Software Assurance (CSA) reframes validation: fewer tests, not less safety. The focus is on workflows that impact patient safety, product quality, and data integrity.

If you are moving from CSV (Computer System Validation) to CSA, the evidence bar stays high. What changes is how you justify test depth and select the most defensible evidence types.

TL;DR

  • CSA means fewer tests, not less safety: shift effort to risk-based assurance.
  • Start with intended use and system boundaries, then classify critical workflows.
  • Choose evidence types by risk (automation, exploratory sessions, supplier evidence, config checks).
  • Keep a short assurance summary plus change-impact rules for updates.
Intended use
  |
  v
Risk assessment
  |
  v
Assurance activity
  |
  v
Evidence package

Why this matters

EU MDR and FDA 21 CFR 820 expect objective evidence for software that supports manufacturing, quality systems, or device performance. FDA CSA guidance modernizes how CSV evidence is produced without lowering expectations.

When evidence feeds an MDR technical file or an FDA 510(k) submission, the rationale for reduced testing must be explicit. Business-wise, CSA avoids re-validation churn when integrations or cloud services change and keeps releases moving.

What “good” looks like in practice

  • Intended use statement with system boundaries and key data flows.
  • Risk assessment mapped to functions that affect safety, quality, and data integrity.
  • Critical workflows defined with acceptance criteria and evidence depth.
  • Assurance activities selected by risk class, not by module count.
  • Traceability from requirements to risks to evidence.
  • Configuration baselines (versions, settings) captured per release.
  • Supplier scope and evidence acceptance criteria documented.

Evidence / Artifacts checklist

  • Intended use and system boundary description (with simple data flow).
  • Risk assessment linking hazards, impact, and test-depth decisions.
  • Risk-based test strategy or assurance plan with rationale.
  • Traceability matrix linking requirements, risks, and evidence.
  • Automated test logs for critical workflows.
  • Exploratory testing notes with objectives and outcomes.
  • Data integrity evidence (access control, audit trail, calculations).
  • Configuration baseline and release/version records.
  • Supplier qualification and evidence review records.
  • Change-impact assessment and re-validation triggers.
  • Deviations, remediation actions, and closures.

Common audit / QA questions

  • How was intended use defined and bounded?
  • Why was test depth reduced for low-risk features?
  • Where is the evidence for data integrity controls?
  • How do you ensure supplier evidence is applicable to scope?
  • What triggers re-validation on change?

Typical failure modes / pitfalls

  • Treating CSA as "no documentation" instead of smarter documentation.
  • Risk assessments that are generic and not tied to test depth.
  • Exploratory sessions performed but not recorded as evidence.
  • Reduced testing on high-risk workflows without rationale.
  • Traceability lost between requirements, risks, and evidence.
  • Configuration baselines missing or inconsistent across releases.

When to call for help

If you need a CSA strategy that holds up in audits and reduces re-validation overhead, a short alignment workshop can prevent weeks of rework. For a risk-based assurance plan, contact me.

Relevant services

Related insights